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Background
Congestion is reported by allergic rhinitis (AR) patients as
the most bothersome nasal symptom. However, ocular
symptoms have the greatest impact on patient quality of
life. A novel treatment which more effectively controls
both nasal and ocular symptoms would fill the gap for an
important unmet need in AR.
Objective
To assess the efficacy of MP29-02* (a novel intranasal for-
mulation of azelastine hydrochloride [AZE] and fluticasone
propionate [FP]) in providing relief from each of the nasal
and ocular symptoms commonly experienced by patients
with seasonal AR (SAR) compared to commercially avail-
able intranasal AZE or FP nasal sprays or placebo.
Methods
Patients (≥12 years old) with moderate-to-severe SAR
(n=610) were randomized into this double-blind, pla-
cebo-controlled, 14-day, parallel-group trial to MP29-
02*, commercially-available AZE or FP nasal sprays, or
placebo (all given as 1 spray/nostril bid [total daily dose:
AZE 548µg; FP 200µg]). The primary efficacy variable
was change from baseline in reflective total nasal symp-
tom score (rTNSS; AM +PM) over 14-days. Secondary
endpoints included change from baseline in each of the
individual nasal and ocular symptoms.
Results
MP29-02* reduced nasal congestion by -1.24 vs -0.86 for
FP (Diff: -0.39; 95% CI -0.65, -0.13; p=0.0034), -0.75 for
AZE (Diff: -0.49; 95% CI: -0.74, -0.24; p=0.0001) and -0.54
for placebo (Diff: -0.70; 95% CI -0.95, -0.45; p<0.0001),
with a relative difference of 54% to FP and 70% to AZE. A
similar and significant superiority of MP29-02* over FP
and AZE was observed for nasal itching (44% to FP, 56%
to AZE), rhinorrhoea (32% to FP; 65% to AZE) and sneez-
ing (49% to FP; 61% to AZE). The most bothersome ocular
symptom of itching was reduced by -1.23 by MP29-02* vs
-0.70 for FP (Diff: -0.53; 95% CI: -0.79, -0.26; p=0.0001),
-0.88 for AZE (Diff: -0.35; 95% CI -0.63, -0.08; p=0.0127)
and -0.44 for placebo (Diff: -0.79, 95% CI -1.04, -0.54;
p<0.0001) with a relative difference of 67% to FP and 44%
to AZE. The relative differences to FP and AZE respec-
tively were 51% and 25% for ocular watering, and 53% and
40% for ocular redness.
Conclusion
MP29-02* provides superior relief from each nasal and
ocular symptom compared to first line AR therapies,
including the most bothersome symptoms of nasal con-
gestion and ocular itching, and can be considered the
drug of choice for AR.
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